Marker Therapeutics (MRKR) Cash from Financing Activities (2010 - 2025)
Marker Therapeutics (MRKR) reported Cash from Financing Activities of $9.9 million for Q3 2025, up 579787.3% year-over-year from N/an in Q3 2024, and up 9863783.0% quarter-over-quarter from $100.0 in Q2 2025.
Marker Therapeutics (MRKR) Cash from Financing Activities (2010 - 2025) Analysis & Trends
Marker Therapeutics (MRKR) has 16 years of Cash from Financing Activities data on file, last reported at $9.9 million in Q3 2025.
- Cash from Financing Activities for Q3 2025 came in at $9.9 million, up 579787.3% year-over-year; the trailing twelve-month figure through Dec 2025 was $9.9 million (down 34.2% YoY), and the FY2025 annual result was $9.9 million, down 34.2% from the prior year.
- Cash from Financing Activities improved to $9.9 million in Q3 2025 per MRKR's latest filing, from $100.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $52.7 million in Q1 2021 and troughed at -$100743.0 in Q2 2021.
- A 5-year average of $5.2 million and a median of $49096.0 in 2024 frame the typical range for Cash from Financing Activities.
- On a YoY basis, Cash from Financing Activities climbed as much as 579787.3% in 2025 and fell as far as 99.78% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at -$100743.0 in 2021, then surged by 237.41% to $138427.0 in 2022, then plunged by 96.29% to $5135.0 in 2023, then surged by 289985.9% to $14.9 million in 2024, then slumped by 33.78% to $9.9 million in 2025.
- Business Quant data shows MRKR's Cash from Financing Activities at $9.9 million in Q3 2025, $100.0 in Q2 2025, and $505.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 85,464.43 |
| 10 | Marker Therapeutics | 28.20 Mn | 28.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 9.86 Mn |
| Sep 30, 2025 | 9.86 Mn |
| Jun 30, 2025 | 100.00 |
| Jun 30, 2025 | 100.00 |
| Mar 31, 2025 | 505.00 |
| Mar 31, 2025 | 505.00 |
| Dec 31, 2024 | 14.90 Mn |
| Dec 31, 2024 | 14.90 Mn |
| Sep 30, 2024 | 1,701.00 |
| Sep 30, 2024 | 1,701.00 |
| Jun 30, 2024 | 44,606.00 |
| Jun 30, 2024 | 44,606.00 |
| Mar 31, 2024 | 49,096.00 |
| Mar 31, 2024 | 49,096.00 |
| Dec 31, 2023 | 5,135.00 |
| Dec 31, 2023 | 5,135.00 |
| Sep 30, 2023 | 479,272.00 |
| Sep 30, 2023 | 479,272.00 |
| Jun 30, 2023 | 736.00 |
| Jun 30, 2023 | 736.00 |